Benzothiazole derivatives in cancer treatment: synthesis and therapeutic potential: review

1.1 Core structure

The benzothiazole moiety is a bicyclic ring system composed of a benzene ring fused with a thiazole ring.^[37] The unique configuration of this core structure is fundamental to the diverse biological activities exhibited by benzothiazole derivatives.^[26] Understanding the core structure and the electronic properties of benzothiazole is crucial for appreciating how these compounds interact with biological targets.^[38] The benzothiazole core consists of a benzene ring (a 6-membered ring with alternating double bonds) fused to a thiazole ring (a 5-membered ring containing a sulfur atom and a nitrogen atom).^[39] The fusion of these rings occurs through 2 carbon atoms, forming a planar and aromatic bicyclic structure. This core is represented chemically as C7H5NS, where the positions on the benzene ring are numbered from 1 to 6 and the positions on the thiazole ring are numbered 2 and 3, with sulfur at position 1 and nitrogen at position 3.^[40]Figure 1 provides a foundational understanding of the benzothiazole core, which is critical for the development of derivatives. Highlighting various substituent positions allows researchers to visualize how modifications can affect biological activity. This structural insight is essential for rational drug design and the exploration of SARs.

The electronic properties of benzothiazole are characterized by its aromaticity, which contributes to its stability and reactivity.^[41] The conjugated π-electron system across the benzene and thiazole rings allows benzothiazole to engage in various π–π interactions, hydrogen bonding, and van der Waals forces with biological macromolecules. These interactions are crucial for the binding affinity and specificity of benzothiazole derivatives toward their biological targets.^[42] Benzothiazole core can be functionalized at various positions to yield a wide array of derivatives with distinct biological properties.^[43] Common functional groups introduced onto the benzothiazole core include amino, hydroxyl, carboxyl, alkyl, and halogen groups.^[44] The choice and position of these substituents play a significant role in modulating the physicochemical and pharmacokinetic properties of the derivatives.^[45]

1.2 Structure–activity relationship (SAR)

SAR of benzothiazole derivatives is a pivotal aspect of medicinal chemistry, as it elucidates how modifications to the chemical structure influence biological activity.^[46] Through systematic alterations of the benzothiazole core and its substituents, researchers can optimize these compounds for enhanced efficacy, selectivity, and reduced toxicity. Table 1 illustrates the relationship between structural modifications of benzothiazole derivatives and their biological activity.^[45] Specific substituents at different positions significantly influence the compounds’ potency, highlighting the importance of SAR studies in designing more effective anticancer agents.^[47] Understanding these relationships aids in the rational design of future derivatives.

Substituents on the benzene ring of the benzothiazole core can significantly impact the compound’s activity and pharmacokinetics.^[48] Electron-donating groups such as hydroxyl (–OH), methoxy (–OCH₃), and amino (–NH₂) groups typically enhance the electron density of the benzene ring, which can increase binding affinity to certain biological targets.^[49] For example, the introduction of an amino group at the 2-position of the benzene ring has been shown to enhance anticancer activity by facilitating stronger interactions with DNA and cellular proteins.^[50] Conversely, electron-withdrawing groups such as nitro (–NO₂), cyano (–CN), and halogens (eg, –F, –Cl, –Br) can reduce electron density, potentially altering the compound’s interaction with biological targets. Halogen substituents can enhance lipophilicity and membrane permeability, which are desirable traits for drug candidates. For instance, the substitution of a fluorine atom at the 4-position of the benzene ring can enhance the compound’s ability to cross cell membranes and increase its metabolic stability. Modifications to the thiazole ring, although less common than benzene ring modifications, can also influence the activity of benzothiazole derivatives. Substituents at the 2-position of the thiazole ring, adjacent to the sulfur atom, can significantly impact the compound’s biological properties.^[51] For example, alkyl or aryl groups at this position can enhance lipophilicity and improve the compound’s interaction with hydrophobic pockets of target proteins. Additionally, substitution at the 3-position, where the nitrogen atom is located, can influence hydrogen bonding interactions with biological targets. Incorporating groups that can form strong hydrogen bonds, such as hydroxyl or amino groups, can enhance the binding affinity and selectivity of benzothiazole derivatives for their targets.

Incorporation of heterocyclic moieties or alkyl chains onto the benzothiazole core can further diversify the biological activity profile of these derivatives.^[52] Heterocyclic groups such as pyridine, pyrazole, or imidazole can introduce new pharmacophores that enhance the compound’s ability to interact with a broader range of biological targets.^[53] For instance, attaching a pyridine ring to the benzothiazole core can improve aqueous solubility and binding to enzymes or receptors. Alkyl chains, on the other hand, can modulate the lipophilicity and membrane permeability of benzothiazole derivatives.^[45] Longer alkyl chains can increase lipophilicity, facilitating the compound’s ability to penetrate cell membranes and reach intracellular targets. However, excessive lipophilicity can lead to poor aqueous solubility and unfavorable pharmacokinetic properties, highlighting the need for a balanced approach in alkyl chain modification.^[54]

Benzothiazole derivatives can be modified to include prodrug moieties that improve pharmacokinetic properties, such as solubility, stability, and bioavailability.^[55] For example, ester or carbamate groups can be introduced to mask polar functional groups, enhancing lipophilicity and facilitating oral absorption.^[56] Once inside the body, enzymatic cleavage releases the active benzothiazole derivative at the site of action.^[57] SAR of benzothiazole derivatives also extends to their pharmacokinetic and pharmacodynamic profiles.^[58] Modifications that enhance the compound’s solubility, stability, and permeability can improve its absorption, distribution, metabolism, and excretion (ADME) properties. For instance, the introduction of polar groups can improve aqueous solubility, facilitating oral or intravenous administration.^[59] Additionally, modifications that increase metabolic stability can prolong the compound’s half-life, reducing the frequency of dosing required for therapeutic efficacy. Several benzothiazole derivatives have been studied extensively for their anticancer properties, providing valuable insights into their SAR. One notable example is the compound 2-(4-aminophenyl)benzothiazole, which has demonstrated potent anticancer activity against a variety of cancer cell lines.^[60] Modifications to the amino group and benzothiazole core have led to the development of analogs with improved potency and selectivity. For instance, introducing halogen substituents at specific positions on the benzene ring has enhanced the compound’s ability to inhibit cell proliferation and induce apoptosis.^[61] Another example is the compound 6-substituted benzothiazole, where modifications at the 6-position of the benzene ring have been explored.^[43] Substituents such as alkyl, aryl, and heterocyclic groups at this position have been shown to influence the compound’s ability to target specific cancer cell types.^[62]

These modifications have also impacted the compound’s pharmacokinetic properties, such as solubility and metabolic stability, further highlighting the importance of SAR in the development of benzothiazole-based anticancer agents.^[63] Despite the promising potential of benzothiazole derivatives, several challenges remain in optimizing their SAR for clinical use. One significant challenge is achieving a balance between potency and selectivity, that is, the selectivity of nonselective kinase inhibition reported by Morphy in 2010,^[64] then Sun et al.^[65] in 2022 inquired in their publication about the cause of drug development failure. While modifications can enhance the compound’s activity against cancer cells, they may also increase off-target effects, leading to toxicity. Therefore, a careful and systematic approach to SAR studies is essential to identify derivatives with an optimal therapeutic window. Additionally, the development of resistance to benzothiazole derivatives is a concern. Cancer cells can adapt to therapeutic pressures, leading to reduced efficacy of the treatment over time. Understanding the mechanisms of resistance and designing derivatives that can overcome or circumvent these mechanisms is a critical area of ongoing research.

2.1 Traditional methods

The synthesis of benzothiazole derivatives has a rich history in organic chemistry, with several classical routes established over the years.^[66] Traditional methods often rely on straightforward chemical reactions that have been well-documented and widely used in various laboratories. Table 2 summarizes the various synthetic methods employed in the development of benzothiazole derivatives. Traditional methods provide a reliable basis but often lack selectivity.^[21] In contrast, modern techniques such as microwave-assisted synthesis and green chemistry approaches offer higher yields and reduced environmental impact.^[34] Understanding these methods is crucial for optimizing synthesis and enhancing the development of effective anticancer agents.^[67]

Figure 2 summarizes the key synthetic approaches to generating benzothiazole derivatives, including classical condensation reactions and innovative microwave-assisted methods.^[33] By comparing the steps involved in each approach, researchers can assess the efficiency and feasibility of different synthetic strategies, informing their choices in developing new compounds.^[39]

• (1) Condensation of o-aminothiophenol with carboxylic acids or derivatives. One of the most common traditional methods for synthesizing benzothiazole derivatives involves the condensation of o-aminothiophenol with carboxylic acids or their derivatives (such as esters, amides, or acid chlorides).^[44] This reaction typically proceeds through the formation of an intermediate amide or ester, followed by cyclization to form the benzothiazole ring. For example, heating o-aminothiophenol with formic acid yields benzothiazole, whereas reaction with other carboxylic acids produces substituted benzothiazoles.^[68]

• (2) Skraup synthesis. The Skraup synthesis, originally developed for the synthesis of quinolines, has been adapted for the preparation of benzothiazoles.^[69] In this method, o-aminothiophenol reacts with an aldehyde (such as formaldehyde) and a strong acid (such as sulfuric acid) in the presence of an oxidizing agent (such as nitrobenzene or ferric chloride). The reaction proceeds through an oxidative cyclization mechanism to yield the benzothiazole core.

• (3) Bucherer–Bergs reaction. Another classical method is the Bucherer–Bergs reaction, which involves the cyclization of o-aminothiophenol with carbon disulfide and an aldehyde or ketone.^[70] The reaction typically uses ammonium hydroxide as a base and produces benzothiazoles through the formation of an intermediate dithiocarbamate, which undergoes cyclization and desulfurization.

• (4) Gabriel–Colman rearrangement. The Gabriel–Colman rearrangement is a method where thioureas react with α-haloketones or α-haloesters to form benzothiazoles.^[71] This reaction proceeds through the formation of an intermediate thiourea derivative, followed by intramolecular cyclization to yield the benzothiazole ring.

• (5) Cyclocondensation reactions. Cyclocondensation reactions involving o-aminothiophenols and various carbonyl compounds (such as ketones, aldehydes, and α,β-unsaturated carbonyl compounds) are also widely used for benzothiazole synthesis.^[72] These reactions often require acidic or basic catalysts to facilitate the cyclization process.

2.2 Modern synthetic techniques

While traditional methods have been invaluable in the synthesis of benzothiazole derivatives, modern synthetic techniques have introduced more efficient, sustainable, and versatile approaches.^[38] These contemporary methods often employ advanced technologies and principles of green chemistry to improve yields, reduce reaction times, and minimize environmental impact.

• (1) Microwave-assisted synthesis. Microwave-assisted synthesis has gained popularity as a rapid and efficient method for preparing benzothiazole derivatives.^[35] Microwave irradiation provides uniform and rapid heating, which can significantly accelerate reaction rates compared with conventional heating methods.^[36] This technique has been applied to various benzothiazole syntheses, including the cyclocondensation of o-aminothiophenols with carboxylic acids or aldehydes. Microwave-assisted reactions typically offer higher yields and shorter reaction times, making them attractive for both academic research and industrial applications.

• (2) Green chemistry approaches. Green chemistry principles emphasize the use of environmentally benign solvents, reagents, and processes to minimize the ecological footprint of chemical synthesis. In the context of benzothiazole derivatives, green chemistry approaches often involve the use of water or ethanol as solvents^[73] and the avoidance of hazardous reagents. For example, water-based reactions have been developed for the cyclocondensation of o-aminothiophenols with aldehydes or ketones, offering a greener alternative to traditional methods.^[74]

• (3) Catalyst-driven processes. Catalysis plays a crucial role in modern synthetic chemistry, providing more efficient and selective pathways for chemical reactions. In benzothiazole synthesis, both homogeneous and heterogeneous catalysts have been employed to enhance reaction rates and selectivity.^[75] Metal catalysts, such as palladium, copper, and gold, have been used in cross-coupling reactions and oxidative cyclization processes to synthesize benzothiazole derivatives. Additionally, organocatalysts, which are small organic molecules that catalyze chemical reactions, have been explored for their ability to facilitate benzothiazole synthesis under mild conditions.

• (4) Photocatalytic and electrocatalytic methods. Photocatalysis and electrocatalysis are emerging techniques that utilize light or electric current to drive chemical reactions. These methods offer unique advantages, such as mild reaction conditions and the ability to harness renewable energy sources. In benzothiazole synthesis, photocatalytic processes have been used to achieve oxidative cyclization of o-aminothiophenols with carbonyl compounds.^[76] Similarly, electrocatalytic methods have been explored for the cyclization of o-aminothiophenols, providing a sustainable approach to benzothiazole synthesis.

• (5) Flow chemistry. Flow chemistry involves conducting chemical reactions in continuously flowing streams rather than in traditional batch reactors. This technique offers several advantages, including improved reaction control, scalability, and safety. Flow chemistry has been applied to the synthesis of benzothiazole derivatives,^[77] allowing for precise control over reaction parameters and efficient production of target compounds. The use of microreactors and continuous flow systems has enabled the rapid synthesis of benzothiazoles with high yields and reproducibility.

2.3 Challenges and solutions

While significant progress has been made in the synthesis of benzothiazole derivatives, several challenges remain. Addressing these challenges is crucial for optimizing synthetic methods and expanding the utility of benzothiazoles in medicinal chemistry and other fields.

• (1) Selectivity and regioselectivity. Achieving high selectivity and regioselectivity in benzothiazole synthesis is a common challenge. The presence of multiple reactive sites on the benzothiazole core can lead to the formation of undesired byproducts or regioisomers. To address this issue, researchers have developed various strategies, including the use of selective catalysts, protecting groups, and directing groups. For example, the introduction of directing groups on the benzene ring can guide the reaction to specific positions, enhancing regioselectivity.

• (2) Functional group tolerance. The tolerance of various functional groups during benzothiazole synthesis is another critical challenge. Functional groups such as hydroxyl, amino, and carboxyl groups can be sensitive to reaction conditions, leading to side reactions or degradation. To overcome this challenge, mild and selective reaction conditions have been developed. For instance, microwave-assisted synthesis and catalyst-driven processes often provide milder conditions that preserve sensitive functional groups.

• (3) Environmental impact. Reducing the environmental impact of benzothiazole synthesis is an ongoing priority. Traditional methods often involve the use of hazardous solvents and reagents, leading to environmental and safety concerns. Green chemistry approaches, such as the use of water or ethanol as solvents and the development of catalyst-driven processes, have been implemented to minimize environmental impact. Additionally, flow chemistry and microwave-assisted synthesis offer more sustainable alternatives by reducing waste and energy consumption.

• (4) Scalability. Scaling up benzothiazole synthesis from laboratory to industrial scale presents several challenges, including maintaining reaction efficiency, yield, and selectivity. Flow chemistry offers a promising solution to scalability issues by enabling continuous production and precise control over reaction parameters. Additionally, the development of robust and scalable catalytic systems is essential for industrial applications.

• (5) Complex molecule synthesis. The synthesis of complex benzothiazole derivatives, such as those with multiple substituents or intricate ring systems, can be challenging. Advanced synthetic techniques, including multistep synthesis, cascade reactions, and one-pot processes, have been developed to address these challenges. For example, multistep synthesis allows for the sequential introduction of various substituents, while cascade reactions enable the formation of complex molecules in a single reaction sequence.

3.1 Cell cycle arrest

The cell cycle is a series of tightly regulated phases that cells undergo to grow and divide. Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. Benzothiazole derivatives have been shown to induce cell cycle arrest, effectively halting the proliferation of cancer cells.

3.2 Apoptosis induction

Apoptosis, or programmed cell death, is a crucial mechanism for eliminating damaged or unwanted cells. In cancer, the apoptotic machinery is often dysregulated, allowing cancer cells to evade death and continue proliferating. Benzothiazole derivatives have been shown to induce apoptosis in cancer cells through various pathways.

• (1) Intrinsic pathway. The intrinsic pathway of apoptosis, also known as the mitochondrial pathway, is initiated by internal cellular stress signals, such as DNA damage or oxidative stress. Benzothiazole derivatives can activate the intrinsic pathway by promoting the release of cytochrome c from the mitochondria into the cytoplasm. This release is mediated by the proapoptotic members of the Bcl-2 family, such as Bax and Bak, which permeabilize the mitochondrial membrane.^[88] Once released, cytochrome c binds to Apaf-1 (apoptotic protease activating factor-1), leading to the formation of the apoptosome.^[89] The apoptosome then activates caspase-9, an initiator caspase, which subsequently activates effector caspases such as caspase-3 and caspase-7.^[90] These effector caspases execute the apoptotic program by cleaving various cellular substrates, leading to characteristic apoptotic features such as DNA fragmentation, membrane blebbing, and cell shrinkage.

• (2) Extrinsic pathway. The extrinsic pathway of apoptosis is triggered by the binding of extracellular death ligands to their respective death receptors on the cell surface.^[91] Benzothiazole derivatives can activate the extrinsic pathway by upregulating the expression of death receptors such as Fas and TRAIL-R (TNF-related apoptosis-inducing ligand receptor). The binding of death ligands such as FasL (Fas ligand) or TRAIL (TNF-related apoptosis-inducing ligand) to these receptors initiates the formation of the death-inducing signaling complex (DISC). The DISC recruits and activates initiator caspases such as caspase-8 and caspase-10. Activated caspase-8 can directly cleave and activate effector caspases, leading to apoptosis. Additionally, caspase-8 can cleave the proapoptotic Bcl-2 family member Bid, generating truncated Bid (tBid), which translocates to the mitochondria and amplifies the intrinsic apoptotic pathway.^[92]

• (3) Regulation by p53. The tumor suppressor p53 plays a central role in regulating apoptosis in response to cellular stress. Benzothiazole derivatives can activate the p53 pathway, leading to the upregulation of proapoptotic genes such as Bax, PUMA, and NOXA.^[93] These genes promote mitochondrial outer membrane permeabilization and the release of cytochrome c, thereby initiating the intrinsic apoptotic pathway. Additionally, p53 can enhance the expression of death receptors, sensitizing cells to extrinsic apoptotic signals.^[94]

3.3 Inhibition of angiogenesis and metastasis

Angiogenesis, the formation of new blood vessels, is a critical process for tumor growth and metastasis. By supplying oxygen and nutrients, angiogenesis supports the rapid proliferation of cancer cells and provides a route for cancer cells to enter the bloodstream and spread to distant sites. Benzothiazole derivatives have been shown to inhibit angiogenesis and metastasis, thereby restricting tumor growth and preventing the dissemination of cancer cells.

• (1) Inhibition of VEGF signaling. VEGF is a key regulator of angiogenesis, promoting the proliferation, migration, and survival of endothelial cells.^[95] Benzothiazole derivatives can inhibit VEGF signaling by targeting the VEGF receptor (VEGFR) on endothelial cells. For example, these compounds can block the binding of VEGF to VEGFR or inhibit the kinase activity of VEGFR, thereby preventing the downstream signaling required for angiogenesis.

• (2) Disruption of endothelial cell function. In addition to inhibiting VEGF signaling, benzothiazole derivatives can directly affect the function of endothelial cells. These compounds can inhibit endothelial cell proliferation, migration, and tube formation, key steps in the angiogenic process. For example, benzothiazole derivatives may disrupt the organization of the cytoskeleton, impairing the ability of endothelial cells to migrate and form new blood vessels.^[96]

• (3) Inhibition of MMPs. MMPs are enzymes that degrade the extracellular matrix (ECM), facilitating the invasion and migration of cancer cells.^[97] Benzothiazole derivatives can inhibit the activity of MMPs, thereby preventing the degradation of the ECM and inhibiting angiogenesis and metastasis. For example, these compounds can bind to the active site of MMPs, blocking their enzymatic activity and reducing the invasiveness of cancer cells.

• (4) Modulation of the tumor microenvironment. The tumor microenvironment plays a crucial role in supporting angiogenesis and metastasis. Benzothiazole derivatives can modulate the tumor microenvironment by targeting various components, such as fibroblasts, immune cells, and the ECM.^[98] For example, these compounds can inhibit the secretion of proangiogenic factors by tumor-associated fibroblasts or enhance the recruitment of antitumor immune cells, thereby creating a microenvironment that is less conducive to tumor growth and spread.

• (5) Targeting hypoxia-inducible factors (HIFs). HIFs are transcription factors that promote the expression of genes involved in angiogenesis and metastasis in response to low oxygen levels.^[99] Benzothiazole derivatives can inhibit the stabilization and activity of HIFs, thereby reducing the expression of proangiogenic and prometastatic genes. For example, these compounds can enhance the degradation of HIF-1α, a key subunit of HIF-1, preventing its accumulation and transcriptional activity under hypoxic conditions.^[100]

3.4 Case studies and examples

• [1] 2-(4-Aminophenyl)benzothiazole. One of the most extensively studied benzothiazole derivatives is 2-(4-aminophenyl)benzothiazole. This compound has demonstrated potent anticancer activity in various preclinical models. It induces cell cycle arrest at the G1 phase by upregulating p21 and p27 and triggers apoptosis through the intrinsic pathway by promoting the release of cytochrome c from the mitochondria.^[101] Additionally, 2-(4-aminophenyl)benzothiazole inhibits angiogenesis by blocking VEGF signaling and disrupting endothelial cell function.

• [2] 5,6-Dimethyl-2-(4-substituted phenyl)benzothiazole. Another benzothiazole derivative, 5,6-dimethyl-2-(4-substituted phenyl)benzothiazole, has shown promise as an anticancer agent. This compound induces cell cycle arrest at the G2/M phase by inhibiting CDK1 and disrupting the formation of the mitotic spindle.^[102] It also triggers apoptosis through both intrinsic and extrinsic pathways and inhibits angiogenesis by targeting VEGF signaling and MMP activity.

• [3] Benzothiazole-based hybrids. Recent research has focused on the development of benzothiazole-based hybrid molecules that combine the benzothiazole core with other bioactive moieties.^[103] These hybrids often exhibit enhanced anticancer activity through multiple mechanisms. For example, a hybrid molecule combining benzothiazole with a histone deacetylase inhibitor has been shown to induce cell cycle arrest, apoptosis, and inhibition of angiogenesis more effectively than either component alone.

4.1 In vitro studies

In vitro studies, conducted in controlled laboratory environments using cell cultures, are the first step in evaluating the anticancer potential of benzothiazole derivatives. These studies provide insights into the molecular mechanisms, cytotoxicity,^[104] and efficacy of these compounds against various cancer cell lines.

• (1) Cytotoxicity and selectivity. Several benzothiazole derivatives have demonstrated potent cytotoxicity against a broad spectrum of cancer cell lines, including breast cancer,^[105] lung cancer, colon cancer, leukemia, and melanoma.^[106] For instance, 2-(4-aminophenyl)benzothiazole has shown significant cytotoxic effects against breast cancer cell lines such as MCF-7 and MDA-MB-231,^[107] with minimal toxicity to normal cells.^[108] This selectivity is crucial for developing therapeutic agents that target cancer cells while sparing healthy tissues.

• (2) Mechanisms of action. In vitro studies have elucidated various mechanisms through which benzothiazole derivatives exert their anticancer effects. These mechanisms include induction of cell cycle arrest, apoptosis, and inhibition of cell proliferation. For example, benzothiazole derivatives have been shown to upregulate p21 and p27, leading to cell cycle arrest at the G1 phase.^[109] Additionally, these compounds can activate caspases, leading to apoptosis through both intrinsic and extrinsic pathways.

• (3) Synergistic effects. Combining benzothiazole derivatives with other anticancer agents has been explored to enhance therapeutic efficacy. In vitro studies have demonstrated synergistic effects when benzothiazole derivatives are used in combination with chemotherapeutic drugs such as doxorubicin, paclitaxel, and cisplatin. For instance, the combination of 2-(4-aminophenyl)benzothiazole with doxorubicin significantly enhances cytotoxicity against breast cancer cell lines compared with either agent alone.^[60] This synergism is often attributed to the complementary mechanisms of action, such as simultaneous induction of cell cycle arrest and apoptosis. Table 4 compares the efficacy of selected benzothiazole derivatives with established anticancer agents across different cancer types. The results indicate that certain derivatives exhibit superior potency against specific cancers, supporting their potential as alternative or complementary therapies. Such comparisons are vital for understanding the role of benzothiazole derivatives in the broader context of cancer treatment.

• (4) Antiangiogenic properties. In vitro studies have also investigated the antiangiogenic properties of benzothiazole derivatives. These compounds can inhibit the proliferation, migration, and tube formation of endothelial cells, key processes involved in angiogenesis. For example, benzothiazole derivatives have been shown to reduce VEGF-induced proliferation and migration of human umbilical vein endothelial cells, indicating their potential to disrupt tumor angiogenesis.

4.2 In vivo studies

In vivo studies, conducted in animal models, are essential for evaluating the efficacy, pharmacokinetics, and safety of benzothiazole derivatives in a physiological context.^[59] These studies provide valuable data on the therapeutic potential and potential adverse effects of these compounds in living organisms. Figure 4 presents empirical data on the efficacy of benzothiazole derivatives, showcasing their performance in both in vitro and in vivo studies.^[47] By illustrating comparative results, researchers can identify which compounds demonstrate the highest potency against specific cancer types, guiding future development efforts and highlighting promising candidates for further investigation.^[79]

Table 5 summarizes key findings from various studies assessing the efficacy of benzothiazole derivatives. The results from in vitro and in vivo studies underscore their significant anticancer potential, while early-phase clinical trials highlight manageable toxicity and encouraging efficacy.^[18] These findings collectively support the ongoing development and investigation of benzothiazole derivatives in clinical settings.

• (1) Efficacy in tumor models. Various benzothiazole derivatives have demonstrated significant anticancer activity in animal models. For instance, 2-(4-aminophenyl)benzothiazole has shown potent antitumor effects in xenograft models of breast cancer.^[110] In these studies, the compound significantly reduces tumor growth and prolongs survival compared with control groups. Similarly, other benzothiazole derivatives have shown efficacy in models of lung cancer, colon cancer, and melanoma.^[111]

• (2) Pharmacokinetics and bioavailability. In vivo studies also assess the pharmacokinetics and bioavailability of benzothiazole derivatives. These studies involve measuring the ADME of the compounds in animal models. For example, pharmacokinetic studies of 2-(4-aminophenyl)benzothiazole have revealed its favorable bioavailability and distribution to tumor tissues, supporting its potential as an effective anticancer agent.^[112]

• (3) Toxicity and safety. Evaluating the toxicity and safety of benzothiazole derivatives is crucial for their development as therapeutic agents. In vivo studies have assessed the potential adverse effects of these compounds on normal tissues and organs. For example, toxicity studies of 2-(4-aminophenyl)benzothiazole in mice have shown minimal toxicity to normal tissues at therapeutic doses.^[113] However, some benzothiazole derivatives may exhibit dose-dependent toxicities, necessitating careful optimization of dosing regimens to balance efficacy and safety.

4.3 Clinical trials

Clinical trials are the final and most critical phase of drug development, assessing the safety, efficacy, and therapeutic potential of benzothiazole derivatives in human patients. While preclinical studies provide promising data, clinical trials are essential to validate these findings and determine the clinical utility of these compounds.

• (1) Early-phase clinical trials. Early-phase clinical trials, including phase I and phase II studies, primarily focus on evaluating the safety, tolerability, and preliminary efficacy of benzothiazole derivatives.^[114] These trials involve a small number of patients and aim to identify the optimal dose and dosing regimen for further studies.

  • (i) Phase I trials. Phase I trials are designed to assess the safety and tolerability of benzothiazole derivatives in human patients. These trials typically involve dose-escalation studies to determine the maximum tolerated dose (MTD) and identify dose-limiting toxicities (DLTs). For example, a phase I trial of a benzothiazole derivative may involve treating patients with escalating doses of the compound and monitoring for adverse effects, such as hematological toxicity or gastrointestinal disturbances.

  • (ii) Phase II trials. Phase II trials aim to evaluate the preliminary efficacy of benzothiazole derivatives in specific cancer types. These trials often involve larger patient cohorts and assess the compound’s ability to induce tumor responses, such as partial or complete remission, and improve progression-free survival (PFS) and overall survival. For instance, a phase II trial of a benzothiazole derivative in breast cancer patients may evaluate the compound’s ability to reduce tumor size and improve survival outcomes compared with standard therapies.

• (2) Late-phase clinical trials. Late-phase clinical trials, including phase III studies, aim to confirm the efficacy and safety of benzothiazole derivatives in larger patient populations and compare their performance to standard treatments.^[115]

  Phase III trials. Phase III trials are pivotal studies that involve large patient cohorts and aim to establish the clinical efficacy and safety of benzothiazole derivatives. These trials often involve randomized controlled trials comparing the benzothiazole derivative to standard therapies or placebo. The primary endpoints of phase III trials typically include overall survival, PFS, and quality of life. For example, a phase III trial of a benzothiazole derivative in lung cancer patients may compare the compound’s efficacy to that of a standard chemotherapy regimen, assessing outcomes such as overall survival and treatment-related adverse effects.

• (3) Current status of clinical trials. As of the latest available data, several benzothiazole derivatives have entered clinical trials, with varying degrees of success.

  • (i) 2-(4-Aminophenyl)benzothiazole derivatives. Some derivatives of 2-(4-aminophenyl)benzothiazole have shown promise in early-phase clinical trials for breast cancer and other malignancies.^[110] These trials have demonstrated manageable toxicity profiles and encouraging preliminary efficacy, warranting further investigation in larger studies.

  • (ii) Other benzothiazole derivatives. Other benzothiazole derivatives are in various stages of clinical development, with ongoing phase I and phase II trials for different cancer types.^[116] These trials aim to establish the safety and preliminary efficacy of these compounds and identify potential biomarkers of response.

5.1 Comparative efficacy

Benzothiazole derivatives have emerged as promising candidates in the landscape of anticancer therapeutics.^[117] Their unique chemical structure, combined with a range of biological activities, positions them favorably compared with existing anticancer agents.

5.2 Drug development

The potential for benzothiazole derivatives in drug development is substantial, particularly in the context of personalized medicine. Their diverse biological activities, favorable pharmacokinetic profiles, and promising preclinical and clinical results provide a strong foundation for future therapeutic advancements.

5.3 Future research directions

While the current research on benzothiazole derivatives has yielded promising results, several gaps and areas of opportunity remain that warrant further exploration.

6.1 Synthesis methods

The review detailed various synthetic approaches to producing benzothiazole derivatives, emphasizing both traditional and modern techniques. Traditional methods, such as the condensation of thiourea with ortho-haloaryl compounds, have been foundational in developing these compounds. However, contemporary synthetic techniques, including microwave-assisted synthesis and green chemistry approaches, have revolutionized the field by offering more efficient, sustainable, and eco-friendly methods. These advancements not only streamline the synthesis process but also allow for the rapid exploration of SARs, facilitating the design of more potent and selective derivatives.

6.2 Therapeutic potential

The therapeutic potential of benzothiazole derivatives in cancer treatment is underscored by their ability to induce apoptosis, inhibit cell proliferation, and disrupt angiogenesis. Their mechanisms of action provide a multifaceted approach to targeting cancer, making them valuable candidates for further development. Preclinical studies have shown promising results, with many derivatives demonstrating potent cytotoxicity against a range of cancer cell lines and superior efficacy compared with existing agents.

Furthermore, ongoing research into the pharmacokinetics, safety profiles, and combination therapies enhances the viability of benzothiazole derivatives as therapeutic agents. The potential for integration into personalized medicine, combined with the identification of biomarkers for patient stratification, positions these compounds at the forefront of innovative cancer treatment strategies.

6.3 Future directions

Despite the promising data, challenges remain in the clinical translation of benzothiazole derivatives. Future research should focus on addressing these gaps, including understanding resistance mechanisms, optimizing drug formulations, and conducting long-term safety studies. Collaborative, multidisciplinary approaches will be essential in advancing benzothiazole derivatives toward successful clinical applications. In conclusion, benzothiazole derivatives represent a promising avenue for cancer therapy, with substantial potential for further development. Their unique synthesis methods and therapeutic efficacy highlight their role in the future landscape of oncology, offering hope for improved outcomes in cancer treatment.